CLINICAL VALIDATION OF DOCETAXEL IN TREATMENT OF ADVANCED BREAST CANCER AND NSCLC

OBJECTIVE:To observe the efficacy and tolerability of docetaxel in treatment of advanced breast cancer and NSCLC.METHODS:Through multicenter prospective study to achieve the objective stated above.RESULTS:Among 29 breast cancer patients,there are 4 CR,12 PR,7 NC and 6 PD after 2～9 cycles of docetaxel treatment in a dose of 75 mg/m2 every 3 weeks,with a total response rate of 55.2%.Among 32 NSCLC patients,there are 7PR,8 NC,17 PD with a total response rate of 21.9%.The ADRs were mainly stomatitis,diarrhea,fatigue,alopecia,skin reactions,myalgia,and rathralgia.Different grade of hypersensitivity was observed in 4 patients,and three of them stopped treatment.9 patients developed fluid retention without discontinuation of treatment.Most of patients developed leucocytopenia but only few developed anemia and thrombocytopenia.One died of cardiovascular failure after one cycle of treatment.CONCLUSION:In treatment of breast cancer and NSCLC docetaxel in a tolerable dosage of 75 mg/m2 has a better efficacy.